Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:41:41.161Z.
Calculation as of: 2026-10-06T15:41:41.161Z.
Quote observation: 2026-10-06T15:40:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f3bc52aaee10dc4864d073eee8720ed85d0d11e7a3d16422bde167dd05b99a5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$89.11M
Price/FCF Ratio
21.14
TTM Avg
49.21
3Y Avg
51.81
5Y Avg
51.81
Market Cap
$94.46M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$96.58M
Price/FCF Ratio
0.02
TTM Avg
3.14
3Y Avg
3.14
5Y Avg
3.14
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| electroCore, Inc. (ECOR) | $91.15M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $92.31M | N/A | 24.77 | 24.77 | 24.77 |
| Biomea Fusion, Inc. (BMEA)vs › | $93.27M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $94.35M | N/A | N/A | N/A | N/A |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.86M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $89.11M | 21.14 | 49.21 | 51.81 | 51.81 |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $94.46M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 4.00 | 5.32 | 4.50 | 8.18 |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $96.58M | 0.02 | 3.14 | 3.14 | 3.14 |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.48M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
